A Phase Ii Study Of Perioperative Therapy For Patients With Resectable And Borderline-Resectable Pancreatic Adenocarcinoma.

4120 Background: Most patients (pts) who undergo surgical resection (SR) for pancreatic ductal adenocarcinoma (PDA) relapse and die. Adjuvant chemotherapy (CT) improves survival compared to observation in randomized trials, but median disease-free survival (DFS) and overall survival (OS) are only 13.4m and 22.1m, respectively. Multiagent CT in the metastatic setting improves DFS and OS compared to gemcitabine (G) alone. Neoadjuvant (NA) treatment of resectable PDA is a rational though unproven strategy to improve standard results. We hypothesized NA multiagent CT and chemoradiotherapy (CRT) paired with SR and adjuvant CT would be manageable and improve the OS of pts with borderline (BR)/resectable (R) PDA. Methods: This was a prospective, single arm, single institution phase II trial. Eligibility included confirmed PDA, R/BR disease, ECOG ≤ 2, and adequate organ function. NA CT (3 cycles of GTX (G 750mg/m2 over 75 minutes and docetaxel 30mg/m2 days (d) 4 and 11, capecitabine (C) 750mg/m2 BID d1-14)) follo...